lungcancer≥ 200mg/dLcolorectalcancerovariancancertobaccouse≥6.5%≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorpneumococcal≥ 100mg/dL≤q2yq1ydiabetesGailmodel40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 126mg/dL< 60y.o.herpeszosterHIVTimedup andgo test52y.o.womenage 55-64 y.o.q3ycardiovasculardiseasemultidoseinitial series,then 1 doseat 2-6months40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsbreastcancerq1ymammogramcommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdepression≥5.7%q1-2ymammogrambased on lifeexpectancy /health statusdementiahormonetherapy2 doses,2-6monthsapartq5yHepatitisBtamoxifenPREVENTequationinsufficientevidenceforscreeninghypertensiondyslipidemiaHepatitisC≥20%3%q2y65y.o.aromataseinhibitors50y.o.60y.o.Tyrer-Cuzickmodelstatin40-70 y.o.,ASCVD ≥10%, lowbleeding riskoverweight/ obesity1 dose; 2doses (2-6monthsapart) ifimmunocompFractureRiskAssessmentToolq15y40-59 y.o.,ASCVD ≥10%, lowbleeding riskcervicalcancer75y.o.40y.o.raloxifeneaspirinanxietylungcancer≥ 200mg/dLcolorectalcancerovariancancertobaccouse≥6.5%≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorpneumococcal≥ 100mg/dL≤q2yq1ydiabetesGailmodel40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 126mg/dL< 60y.o.herpeszosterHIVTimedup andgo test52y.o.womenage 55-64 y.o.q3ycardiovasculardiseasemultidoseinitial series,then 1 doseat 2-6months40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsbreastcancerq1ymammogramcommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdepression≥5.7%q1-2ymammogrambased on lifeexpectancy /health statusdementiahormonetherapy2 doses,2-6monthsapartq5yHepatitisBtamoxifenPREVENTequationinsufficientevidenceforscreeninghypertensiondyslipidemiaHepatitisC≥20%3%q2y65y.o.aromataseinhibitors50y.o.60y.o.Tyrer-Cuzickmodelstatin40-70 y.o.,ASCVD ≥10%, lowbleeding riskoverweight/ obesity1 dose; 2doses (2-6monthsapart) ifimmunocompFractureRiskAssessmentToolq15y40-59 y.o.,ASCVD ≥10%, lowbleeding riskcervicalcancer75y.o.40y.o.raloxifeneaspirinanxiety

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. lung cancer
  2. ≥ 200 mg/dL
  3. colorectal cancer
  4. ovarian cancer
  5. tobacco use
  6. ≥ 6.5%
  7. ≥ 140 mg/dL
  8. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  9. pneumococcal
  10. ≥ 100 mg/dL
  11. ≤ q2y
  12. q1y
  13. diabetes
  14. Gail model
  15. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  16. ≥ 126 mg/dL
  17. < 60 y.o.
  18. herpes zoster
  19. HIV
  20. Timed up and go test
  21. 52 y.o.
  22. women age 55-64 y.o.
  23. q3y
  24. cardiovascular disease
  25. multidose initial series, then 1 dose at 2-6 months
  26. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  27. breast cancer
  28. q1y mammogram
  29. community-dwelling, postmenopausal women
  30. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  31. depression
  32. ≥ 5.7%
  33. q1-2y mammogram based on life expectancy / health status
  34. dementia
  35. hormone therapy
  36. 2 doses, 2-6 months apart
  37. q5y
  38. Hepatitis B
  39. tamoxifen
  40. PREVENT equation
  41. insufficient evidence for screening
  42. hypertension
  43. dyslipidemia
  44. Hepatitis C
  45. ≥ 20%
  46. 3%
  47. q2y
  48. 65 y.o.
  49. aromatase inhibitors
  50. 50 y.o.
  51. 60 y.o.
  52. Tyrer-Cuzick model
  53. statin
  54. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  55. overweight / obesity
  56. 1 dose; 2 doses (2-6 months apart) if immunocomp
  57. Fracture Risk Assessment Tool
  58. q15y
  59. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  60. cervical cancer
  61. 75 y.o.
  62. 40 y.o.
  63. raloxifene
  64. aspirin
  65. anxiety